Manufacturer of Neratinib

Neratinib (Neratinib) The original drug is marketed in China as neratinib maleate tablets and sold under the trade name Heli'an. Neratinib is an oral irreversible inhibitor of human epidermal growth factor receptor HER1 (EGFR), HER2 and HER4. It was originally developed by Wyeth (now Pfizer) and now developed by Puma Biotechnology. It is mainly used to treat HER2-positive (HER+) breast cancer.

In the United States, neratinib is approved for the long-term adjuvant treatment of patients with HER2+ early-stage breast cancer who have previously received trastuzumab-based therapy (Trastuz Approval was based on the ExteNET trial, a multicenter, randomized, double-blind, placebo-controlled trial following adjuvant trastuzumab therapy. Neratinib is also indicated as monotherapy and/or in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more anti-HER2-based treatment regimens in the metastatic setting.

NeratinibThe original drug has entered the scope of Class B medical insurance after being launched in China, but it is only reimbursed for patients who meet the indications. SpecificationThe price of each box of 40mg*180 tablets may be around 7,000 yuan. Generic drugs of neratinib are also sold overseas. The drug ingredients are basically the same as those of the original drug. The price of 40mg*180 tablets produced by Bangladesh pharmaceutical factory may be around 4,000 yuan per box (the price may fluctuate due to the exchange rate). For more information about overseas drugs and specific prices, please consult Yaode Medical Consultant.